The Board approved AFR for Qtr/year ended 31 March 2025.

Revenue declinedNet loss reportedEBITDA margin compressionNegative operating cash flowDebt to equity above the thresholdResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.0%Reaction day

₹18.27

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-2.0% vs market

Pharmaceuticals peers, median of 147sector+0.1%-2.2% vs sector

On the reaction day the stock moved 2.0 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.0-0.1-2.0+0.1-2.2

Next day

-5.0+0.2-5.3-0.0-5.0

-5.0+0.6-5.6+0.8-5.9

-6.4+0.9-7.3+0.3-6.7

-5.9+1.0-6.9+0.0-5.9

-10.0+0.7-10.7-0.6-9.4

-10.2+1.8-12.0+0.0-10.2

15d

-7.2+1.7-8.9-0.8-6.4

-8.9+3.1-11.9-0.6-8.3

—+1.7—+0.6—

+25.0-1.0+26.0-3.0+28.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Brawn Biotech Ltd's Board has approved the audited financial results for Q4 FY25 and the full year ended 31 March 2025. Revenue from operations fell sharply to Rs. 1,538.05 lakhs in FY25 from Rs. 3,558.90 lakhs in FY24, a drop of nearly 57%. The company reported a net loss of Rs. 178.07 lakhs for FY25, slightly narrower than the Rs. 184.42 lakhs loss in FY24, with Q4 FY25 alone showing a loss of Rs. 63.88 lakhs. Total equity eroded to Rs. 336.23 lakhs (from Rs. 506.50 lakhs), while total liabilities rose to Rs. 1,712.57 lakhs, pushing the debt-to-equity ratio above 5x. Cash flow from operations turned negative at Rs. (79.41) lakhs versus a positive Rs. 222.08 lakhs last year.

Likely market impact

Continuing losses, a steep revenue decline, negative operating cash flow, and a very high debt-to-equity ratio point to significant financial stress. Shareholders should view this as a negative development, with risks to solvency and going-concern status if performance does not improve.